Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants.
Belgium
COVID-19
SARS-CoV-2
genomic surveillance
next-generation sequencing
variants of concern
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
20 10 2022
20 10 2022
Historique:
received:
31
08
2022
revised:
14
10
2022
accepted:
17
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
An adequate SARS-CoV-2 genomic surveillance strategy has proven to be essential for countries to obtain a thorough understanding of the variants and lineages being imported and successfully established within their borders. During 2020, genomic surveillance in Belgium was not structurally implemented but performed by individual research laboratories that had to acquire the necessary funds themselves to perform this important task. At the start of 2021, a nationwide genomic surveillance consortium was established in Belgium to markedly increase the country's genomic sequencing efforts (both in terms of intensity and representativeness), to perform quality control among participating laboratories, and to enable coordination and collaboration of research projects and publications. We here discuss the genomic surveillance efforts in Belgium before and after the establishment of its genomic sequencing consortium, provide an overview of the specifics of the consortium, and explore more details regarding the scientific studies that have been published as a result of the increased number of Belgian SARS-CoV-2 genomes that have become available.
Identifiants
pubmed: 36298856
pii: v14102301
doi: 10.3390/v14102301
pmc: PMC9612291
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Viruses. 2022 Apr 03;14(4):
pubmed: 35458482
PLoS One. 2022 Jun 3;17(6):e0269138
pubmed: 35657787
Sci Rep. 2021 Sep 17;11(1):18580
pubmed: 34535691
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794443
Sci Transl Med. 2022 Feb 23;14(633):eabk3445
pubmed: 35014856
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Nat Commun. 2022 Mar 3;13(1):1152
pubmed: 35241661
Nature. 2021 Jul;595(7869):713-717
pubmed: 34192736
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Pathogens. 2020 Mar 23;9(3):
pubmed: 32210130
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Mol Biol Evol. 2021 Apr 13;38(4):1608-1613
pubmed: 33316043
Nat Med. 2022 Jun;28(6):1110-1115
pubmed: 35637337
Nat Commun. 2022 Nov 16;13(1):7003
pubmed: 36385137
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Int J Infect Dis. 2022 Sep;122:212-214
pubmed: 35605952
NPJ Vaccines. 2022 Mar 8;7(1):35
pubmed: 35260578
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nat Commun. 2021 Nov 16;12(1):6612
pubmed: 34785663
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Science. 2021 Jan 29;371(6528):466-467
pubmed: 33510015
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):32842-32844
pubmed: 33310901
Epidemics. 2022 Sep;40:100589
pubmed: 35691101
Microbiol Resour Announc. 2022 Feb 17;11(2):e0116121
pubmed: 35112910
Viruses. 2022 Jun 14;14(6):
pubmed: 35746768
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Viruses. 2021 Jul 13;13(7):
pubmed: 34372565
Nat Aging. 2023 Jun;3(6):722-733
pubmed: 37217661
Viruses. 2020 Aug 27;12(9):
pubmed: 32867108
Viruses. 2022 May 31;14(6):
pubmed: 35746671
Mol Biol Evol. 2022 Apr 11;39(4):
pubmed: 35325204
Nat Commun. 2020 Oct 9;11(1):5110
pubmed: 33037213
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225